Abstract:Abstract Dialkoxyphenyl compounds have been reported to possess anti-inflammatory activity through inhibition of phosphodieseterase (PDE) type IV. In this study, a series of derivatives of dialkoxyphenyl compounds with an oxime group, which is generally known to be one of the biologically active functional groups, were prepared and evaluated for their ability to inhibit the production of inflammatory mediators in activated macrophages and the proliferation of lymphocytes. The structure–activity relationship (SAR) study with 12 compounds on tumour necrosis factor (TNF)-α inhibition, analysed by the oxime geometry and different size of spacers between the oxime and phenyl group, indicated that there might be at least three possible hydrogen bonding sites in the inhibitor binding pocket of PDE IV. Of them, compound 6 clearly displayed the highest inhibitory effect on in-vitro TNF-α production from lipopolysaccharide (LPS)-stimulated RAW264.7 cells. Compound 6 also suppressed in-vivo TNF-α release from LPS-primed mice, a level comparable with that of the standard PDE IV inhibitor, rolipram. In addition, oxime compounds also significantly inhibited both nitric oxide production from activated RAW264.7 cells and T lymphocyte proliferation elicited by concanavalin A but not IL-2. The data suggest that the oxime group may act as a functional group, capable of interacting with the inhibitor-binding pocket of target PDE IV. Therefore, it is conceivable that compound 6 may have the potential either to be developed as a new anti-inflammatory drug or to be used to develop more potent analogues.

Cryptopleurine Analogs With Modification Of E Ring Exhibit Different Mechanism To Rac-Cryptopleurine And Tylophorine

Structure-activity Relationships of Cryptopleurine Analogs with E-ring Modifications As Anti-Hepatitis C Virus Agents.

Antitumor Agents 295. E-ring Hydroxylated Antofine and Cryptopleurine Analogues As Antiproliferative Agents: Design, Synthesis, and Mechanistic Studies.

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Antitumor Agents. 274. A New Synthetic Strategy for E-ring SAR Study of Antofine and Cryptopleurine Analogues.

Antitumor Agents 288: Design, Synthesis, SAR, and Biological Studies of Novel Heteroatom-Incorporated Antofine and Cryptopleurine Analogues As Potent and Selective Antitumor Agents.

Antitumor Agents 268. Design, Synthesis, and Mechanistic Studies of New 9-Substituted Phenanthrene-Based Tylophorine Analogues As Potent Cytotoxic Agents.

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Eucryphin Analog's Total Synthesis, Anti-inflammatory Activity for DNFB-Induced Contact Hypersensitivity and Structure-activity Relationship

Cytotoxic Analogues of Marine Diterpenoid Plumisclerin A by Shifting the Lipophilic Branch on the Characteristic Tricyclic Core.

Differential modulation of FXR activity by chlorophacinone and ivermectin analogs

Phakefustatins A–C: Kynurenine-Bearing Cycloheptapeptides As RXRα Modulators from the Marine Sponge Phakellia Fusca

Effects of dialkoxylphenyl compounds with oxime group on macrophage function and the proliferation of lymphocytes

Efficient synthesis and cytotoxic activity of polysubstituted thieno[2,3-d]pyrimidine derivatives

A New Phenanthrene with a Spirolactone from Dendrobium Chrysanthum and Its Anti-Inflammatory Activities

Design, synthesis, and pharmacological activities of dynorphin A analogues cyclized by ring-closing metathesis.

Progress on structural modification of Tetrandrine with wide range of pharmacological activities

Design, Synthesis, and Evaluation of Novel CXCR4 Antagonists Based on an Aminoquinoline Template.

DNA Interaction and Cleavage Modes of Anthraquinone-Fused Enediynes: A Study on Tiancimycins, Yangpumicins, and Their Semisynthetic Analogues

Undescribed ecdysteroids and phenolic glycosides from the roots of Cyathula officinalis Kuan and their anti-inflammatory activity in LPS-induced RAW 264.7 macrophages in vitro

From RORγt Agonist to Two Types of RORγt Inverse Agonists.